Researchers at Thomas Jefferson University have found a new way to help. Their study showed that using two diabetes ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

This discovery shows that a thoughtful combination of medicines can make a big difference in treating complex cases of Type 2 ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to ...

There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

Vivani expects these results to support the potential application of this GLP-1 (exenatide) implant in the treatment of type 2 diabetes and other diseases for which GLP-1 treatment has ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam ...